Skip to main content
  • Simple nasal wash reduces COVID-19 severity

    Simple nasal washes with mild saline water can prevent hospitalisation and deaths from COVID-19, if applied twice daily following a positive diagnosis, according to research led by the US-based Augusta University.

  • Common mutation linked to COVID mortality

    it may be the most baffling quirk of COVID: What manifests as minor, flu-like symptoms in some individuals spirals into severe disease, disability, or even death in others. A new paper published in Nature may explain the genetic underpinnings of this dichotomy.

  • Neutralizing antibodies from single COVID-19 booster steadily decline

    Neutralizing antibody levels against the original COVID-19 virus and omicron variants in vaccinated adults tend to decline by at least 15% per month after a single booster shot, a new study using serum from human blood samples suggests. 

    Data from two adults in the same study who had a dramatic loss in antibodies but received a second booster showed that the second dose completely restored antibodies to protective levels.

  • Myocarditis after COVID-19 vaccines remain rare

    A new study from Israel found that the risk of developing myocarditis among males ages 16 to 19 years was about 1 in 15,000 after third dose of the Pfizer-BioNTech COVID-19 vaccine, and the cases were rare and mild, according to new research published today in the American Heart Association’s flagship journal Circulation.

  • Pfizer and BioNTech Advance COVID-19 Vaccine Strategy on Enhanced Spike Protein Design

    Pfizer Inc and BioNTech SE announced that the companies have initiated a randomized, active-controlled, observer-blind, Phase 2 study to evaluate the safety, tolerability, and immune response of an enhanced COVID-19 mRNA-based vaccine candidate at a 30 µg dose level. This next-generation bivalent COVID-19 vaccine candidate, BNT162b5, consists of RNAs encoding enhanced prefusion spike proteins for the SARS-CoV-2 ancestral strain (wild-type) and an Omicron variant.

  • Patients treated with monoclonal antibodies during COVID-19 delta surge had low rates of severe disease ; study finds

    A study of 10,775 high-risk adult patients during the COVID-19 delta variant surge in late 2021 finds that treatment with one of three anti-spike neutralizing monoclonal antibodies for mild to moderate symptoms led to low rates of severe disease, hospitalization, ICU admission and mortality, according to Mayo Clinic researchers.

  • Biological E gets WHO nod for JnJ COVID vaccine production

    Biological E gets the World Health Organisation (WHO) approval to be an additional facility for production of Johnson & Johnson COVID-19 vaccine.

    The Johnson & Johnson COVID-19 vaccine consists of a replication-incompetent recombinant adenovirus type 26 (Ad26) viral vector expressing the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike (S) protein in a stabilized conformation.

  • Vacancy for Project Assistant at Netaji Subhash University of Technology

    One of Indias most reputed institutions in the domain of technical education, NSIT has carved a niche for itself - both nationally and internationally - for excellence in education and research. The overall environment in the institution is highly conducive for growth and provides a quality learning atmosphere.

    Post : Project Assistant

  • LumiraDx Receives WHO Emergency Use Listing for SARS-CoV-2 Ag Test

    LumiraDx Limited a next-generation point of care diagnostics company, announced today that its rapid COVID-19 antigen assay, LumiraDx SARS-CoV-2 Ag Test has successfully received the Emergency Use Listing (EUL) by the World Health Organization (WHO) in their latest response effort to combat COVID-19.

  • CCMB has developed ingenious mRNA vaccine against COVID-19

    CSIR-CCMB has developed an ingenious mRNA vaccine against COVID-19 which has completed experiments in the lab and on mice. It is based on the Moderna model, but has been built with the information available in the open and CCMB technology and materials.

Subscribe to COVID-19

Search this website